LRRK2 and Parkinson disease: A Bonferroni post hoc analysis showed that the LRRK2+ PD group had significantly higher CSF LRRK2 compared to healthy controls (p = 0.0013), idiopathic PD (p = 0.0007), and compared to non-manifesting LRRK2 carriers (p = 0.029).